DiaMedica Therapeutics Inc

DMAC is in a Stage 4 decline despite a long-term uptrend, with a dominant lower high/low structure driving medium-term bearish bias. Price rallies have been rejected at declining EMAs and the 50-DMA, indicating supply control. A short-term uptick above EMAs reduces immediate sell timing, suggesting deferred execution. Trimming into resistance zones aligns with structural downtrend while awaiting clearer follow-through.

• ↑Interim preeclampsia data shows DM-199 significantly lowers systolic blood pressure.
• ↑$59.9M in cash and equivalents secures funding for clinical studies through 2027.
• ↓FY25 net loss of $29.1M and negative earnings yield raise runway concerns.